Clinicians' attitudes to oncology clinical practice guidelines and the barriers and facilitators to adherence: a mixed methods study protocol.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
23 03 2020
Historique:
entrez: 25 3 2020
pubmed: 25 3 2020
medline: 17 2 2021
Statut: epublish

Résumé

Clinical practice guidelines (CPGs) are designed to reduce inappropriate clinical variation and improve the quality of care. Barriers to CPGs include a lack of awareness of CPGs, access to them, time pressures and concerns regarding the evidence underpinning CPG development, implementation and dissemination. The objectives of this study are to assess clinicians' attitudes to CPGs for cancer treatment and the perceived barriers to and facilitators of CPG adherence in order to inform the implementation of cancer treatment CPGs. A mixed methods study will be conducted using a three-phase, sequential design, with each phase informing the next. In phase 1, a qualitative study using recorded interviews will investigate clinicians' attitudes to CPGs for cancer treatment and perceptions of barriers and facilitators to CPG adherence (n=30); interview transcripts will be analysed thematically. In phase 2, a survey will quantify the frequency of attitudes, barriers and facilitators identified in phase 1, in a broader clinical sample (n=200). In phase 3, a workshop forum will be held to facilitate discussions examining the implications of phase 1 and 2 findings for cancer CPG implementation strategies (n=40) leading to recommendations for improvements to practice. The workshop discussion will be recorded, and the transcript will be analysed thematically. This study has received ethics approval in New South Wales, Australia (2019/ETH11722, #52019568810127). Study findings will be published in peer-reviewed journals and will form part of a doctoral thesis and be presented at national and international conferences.

Identifiants

pubmed: 32205377
pii: bmjopen-2019-035448
doi: 10.1136/bmjopen-2019-035448
pmc: PMC7103843
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e035448

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Asia Pac J Clin Oncol. 2017 Oct;13(5):e373-e380
pubmed: 27726297
Obstet Gynecol. 2013 Jun;121(6):1226-34
pubmed: 23812456
J Eval Clin Pract. 2018 Feb;24(1):117-126
pubmed: 28371050
Cochrane Database Syst Rev. 2019 Jun 24;6:CD000125
pubmed: 31232458
Clin Breast Cancer. 2015 Aug;15(4):e189-95
pubmed: 25913904
J Oncol Pract. 2012 Jul;8(4):253-9
pubmed: 23180992
Implement Sci. 2011 Apr 23;6:42
pubmed: 21513547
J Clin Oncol. 2011 Dec 20;29(36):4769-75
pubmed: 22084372
Am J Surg. 2006 Oct;192(4):525-7
pubmed: 16978966
Health Serv Res. 2013 Dec;48(6 Pt 2):2134-56
pubmed: 24279835
J Eval Clin Pract. 2018 Feb;24(1):135-144
pubmed: 28474459
BMC Med Inform Decis Mak. 2008 Sep 12;8:38
pubmed: 18789150
Breast. 2003 Apr;12(2):136-41
pubmed: 14659343
J Clin Oncol. 2004 Jun 1;22(11):2233-9
pubmed: 15169812
Implement Sci. 2015 Apr 21;10:54
pubmed: 25895908
JAMA. 1999 Oct 20;282(15):1458-65
pubmed: 10535437
J Eval Clin Pract. 2007 Aug;13(4):607-15
pubmed: 17683303
BJU Int. 2016 Apr;117 Suppl 4:35-44
pubmed: 25585989
J Clin Oncol. 2012 Mar 20;30(9):972-9
pubmed: 22355049
Br J Cancer. 2012 Mar 13;106(6):1021-6
pubmed: 22374464
Clin Oncol (R Coll Radiol). 2016 Oct;28(10):639-47
pubmed: 27211609
Breast. 2016 Oct;29:126-31
pubmed: 27484016
Ann Oncol. 2013 Jun;24(6):1685-91
pubmed: 23446092
Am J Med Qual. 2007 May-Jun;22(3):170-6
pubmed: 17485558
Cochrane Database Syst Rev. 2016 Aug 22;(8):CD010669
pubmed: 27546228
Adv Med Educ Pract. 2016 Dec 13;7:673-680
pubmed: 28008300
Radiother Oncol. 2019 Dec;141:41-47
pubmed: 31606225
Fam Pract. 1996 Dec;13(6):522-5
pubmed: 9023528
Acad Med. 2014 Sep;89(9):1245-51
pubmed: 24979285
J Contin Educ Health Prof. 2004 Fall;24 Suppl 1:S31-7
pubmed: 15712775
BMJ. 2001 May 5;322(7294):1115-7
pubmed: 11337448

Auteurs

Mia Bierbaum (M)

Australian Institute of Health Innovation, Macquarie University, Sydney, New South Wales, Australia mia.bierbaum@hdr.mq.edu.au.

Jeffrey Braithwaite (J)

Australian Institute of Health Innovation, Macquarie University, Sydney, New South Wales, Australia.
Centre for Research Excellence in Implementation Science in Oncology, Australian Institute of Health Innovation, Macquarie University, Sydney, New South Wales, Australia.

Gaston Arnolda (G)

Australian Institute of Health Innovation, Macquarie University, Sydney, New South Wales, Australia.
Centre for Research Excellence in Implementation Science in Oncology, Australian Institute of Health Innovation, Macquarie University, Sydney, New South Wales, Australia.

Geoffrey P Delaney (GP)

Centre for Research Excellence in Implementation Science in Oncology, Australian Institute of Health Innovation, Macquarie University, Sydney, New South Wales, Australia.
Liverpool Cancer Therapy Centre, Liverpool, New South Wales, Australia.
University of New South Wales South Western Sydney Clinical School, Liverpool, New South Wales, Australia.

Winston Liauw (W)

Centre for Research Excellence in Implementation Science in Oncology, Australian Institute of Health Innovation, Macquarie University, Sydney, New South Wales, Australia.
Translational Cancer Research Network, Lowy Cancer Research Centre, University of New South Wales, Sydney, New South Wales, Australia.
Cancer Services, South Eastern Sydney Local Health District, Kogarah, New South Wales, Australia.

Richard Kefford (R)

Centre for Research Excellence in Implementation Science in Oncology, Australian Institute of Health Innovation, Macquarie University, Sydney, New South Wales, Australia.
Department of Clinical Medicine, Macquarie University, Sydney, New South Wales, Australia.
Melanoma Institute Australia, North Sydney, New South Wales, Australia.

Yvonne Tran (Y)

Australian Institute of Health Innovation, Macquarie University, Sydney, New South Wales, Australia.
Centre for Research Excellence in Implementation Science in Oncology, Australian Institute of Health Innovation, Macquarie University, Sydney, New South Wales, Australia.

Bróna Nic Giolla Easpaig (B)

Australian Institute of Health Innovation, Macquarie University, Sydney, New South Wales, Australia.
Centre for Research Excellence in Implementation Science in Oncology, Australian Institute of Health Innovation, Macquarie University, Sydney, New South Wales, Australia.

Frances Rapport (F)

Australian Institute of Health Innovation, Macquarie University, Sydney, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH